2017 American Transplant Congress
Lower Mean Tacrolimus Troughs Increase Risk of De Novo Donor-Specific Antibodies in the First Year of Kidney Transplant.
University of Colorado, Aurora, CO
Development of de novo donor-specific antibodies (dnDSA) is the first step in the evolution of antibody-mediated rejection, which constitutes the leading cause of death-censored graft…2017 American Transplant Congress
Complement Activating Anti-HLA Antibodies: Identification of Specific Histo-Mmolecular Phenotype of Rejection for Complement-Targeting Therapy.
Addressing the heterogeneity of antibody-mediated allograft rejection by identifying phenotypes based on pathophysiology is critical for improving outcomes in transplantation. We investigated whether complement-binding anti-HLA…2017 American Transplant Congress
Blood Transfusion Before Organ Transplant: Patient Sensitization and Outcomes.
Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN
BackgroundBlood transfusions (Btf) can cause alloimmunization to HLA antigens. Antibodies to HLA (HLAb) can increase patients' calculated panel reactive assay (cPRA) and make it more…2017 American Transplant Congress
Association of Non-HLA Antibodies with Histological Changes of Antibody Mediated Injury in Kidney Transplantation.
1Division of Nephrology, University of Washington, Seattle; 2Bloodworks NW, Seattle
Solid phase assays, particularly single-antigen beads, have substantially increased the sensitivity and accuracy of antibody detection in transplantation. However, donor specific antibodies(DSA) against human leukocyte…2017 American Transplant Congress
Clinical Impact of Strength and Class of Pre transplant Donor Specific Antibody on Kidney Transplant Recipient Receiving Steroid Free Maintenance Immunosupression Regimen.
Renal Transplant, Indiana University School of Medicine, Indianapolis, IN
Background: The class and strength of pre- transplant DSA has been described as playing a role in determining future risk of acute rejection (AR) and…2017 American Transplant Congress
Kidney Transplant Rejection Associated with DQ Eplet Mismatches.
The presence of anti-HLA antibodies is associated with acute rejection, allograft dysfunction and earlier graft loss. HLA antibodies are recognized as being specific to these…2017 American Transplant Congress
Safety and Activity of Anti-C1s Humanized Monoclonal Antibody TNT009 in Late Antibody-Mediated Kidney Allograft Rejection – Results of a First-in-Human Phase 1 Trial.
Study purpose:The classical pathway (CP) of complement may significantly contribute to antibody-mediated rejection (ABMR). Blockade of CP key component C1 may be a promising strategy…2017 American Transplant Congress
Update of a Placebo-Controlled Trial of C1 Esterase Inhibitor for Prevention of Antibody Mediated Rejection (ABMR) in Highly-HLA Sensitized Patients.
Kidney Transplant, Cedars-Sinai Medical Center, LA, CA
INTRODUCTION: Desensitization (DES) strategies focus primarily on antibody reduction using IVIG, rituximab ± PLEX to prevent DSA-induced ABMR and rebound B-cell activity. Pathologic features of…2017 American Transplant Congress
Healthcare Resource Utilization for Patients with Donor-Specific Antibodies Post-Kidney Transplantation.
Formation of de novo donor-specific antibodies (dnDSA) against human leukocyte antigens (HLA) contributes to inferior kidney transplant (KT) outcomes. No data exist on healthcare resource…2017 American Transplant Congress
Isolated Angiotensin II Receptor Type I Antibodies (AT1R) Are Not Associated with Active Antibody Mediated Rejection (ABMR) in Pediatric Renal Transplant Recipients.
Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, CA
Intro: Donor specific antibodies (DSAs) detected post transplant are associated with ABMR and graft dysfunction. The role of non-HLA antibodies especially angiotensin II receptor type…
- « Previous Page
- 1
- …
- 29
- 30
- 31
- 32
- 33
- …
- 47
- Next Page »